Purified using protein G column chromatography from culture supernatant of hybridoma cultured in a medium containing bovine IgG-depleted (approximately 95%) fetal bovine serum. Filtered through a 0.22 micrometer membrane.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50. Detects a band of approximately 130 kDa (predicted molecular weight: 106 kDa).
Use at an assay dependent dilution.
Use at 10 µg/mg of lysate.
May be a transcription regulator involved in cell-cycle progression and skeletal muscle differentiation. May repress GTF2I transcriptional functions, by preventing its nuclear residency, or by inhibiting its transcriptional activation. May contribute to slow-twitch fiber type specificity during myogenesis and in regenerating muscles. Binds troponin I slow-muscle fiber enhancer (USE B1). Binds specifically and with high affinity to the EFG sequences derived from the early enhancer of HOXC8.
Highly expressed in adult skeletal muscle, heart, fibroblast, bone and fetal tissues. Expressed at lower levels in all other tissues tested.
Involvement in disease
Note=GTF2IRD1 is located in the Williams-Beuren syndrome (WBS) critical region. WBS results from a hemizygous deletion of several genes on chromosome 7q11.23, thought to arise as a consequence of unequal crossing over between highly homologous low-copy repeat sequences flanking the deleted region. Haploinsufficiency of GTF2IRD1 may be the cause of certain cardiovascular and musculo-skeletal abnormalities observed in the disease.
Belongs to the TFII-I family. Contains 5 GTF2I-like repeats.
Highly expressed in developing and regenerating muscles, at the time of myofiber diversification.
The N-terminal half may have an activating activity.
ab51524 used at 5µg/500µg RIPA lysate of HeLa cells transfected with GTF2IRD1.
Western blot was labelled with ab51524 at 1/50 dilution followed by Mouse IgG antibody at 1/2500 dilution. Developed using the ECL technique.